Multicenter study to evaluate the efficacy of 1L Ascorbic acid PEG plus linaclotide for bowel preparation

Multicenter study to evaluate the efficacy of 1L Ascorbic acid PEG plus linaclotide for bowel preparation: a randomized, endoscopist-blinded, controlled trial - Apple trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051210162

Enrollment

1464

Registered

2022-01-28

Start date

2022-04-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients who require colonoscopy colonoscopy

Interventions

Patients receive linaclotide 0.5 mg or sennoside 24 mg prior to 1-L PEG-Asc.

D002400

Solution, Bowel Preparation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients who were scheduled for elective colonoscopy 2) patients who aged over 20 years old and under 85 years old 3) patients who were able to fill in the informed consent form for participation

Exclusion criteria

Exclusion criteria: 1) severe heart failure (NYHA class III or IV) 2) severe hepatic failure (Child-Pugh C) 3) active inflammatory bowel disease 4) dementia 5) allergy to Moviprep, sennoside or linaclotide 6) advanced colorectal cancer 7) intestinal resection 8) past history of participance in this study

Design outcomes

Primary

Measure	Time frame
inadequate bowel preparation rate scored by Boston Bowel Preparation Scale (BBPS)	—

Secondary

Measure	Time frame
procedure-related parameters, safety and tolerability	—

Contacts

Public ContactAkira Higashimori

Osaka Metropolitan University Hospital

higamo@omu.ac.jp+81-6-6645-2121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026